Medindia
Medindia LOGIN REGISTER
Advertisement

InterveneRx and Allied National Launch First Value-based Benefits Design for Specialty Drugs

Friday, February 1, 2019 Genetics & Stem Cells News
Advertisement
Copay penalties and incentives to be used to engage members in specialty drug management.

PARK CITY, Utah, Jan. 31, 2019 /PRNewswire-PRWeb/ -- Based on the success of its initial specialty drug care management program, Allied National, Inc., a leading third party administrator, is expanding its partnership with InterveneRX, a specialty drug management company. This expansion of services will offer the first of its kind value-based benefit design for specialty drugs.
Advertisement

This unique partnership carves out all prescription drug prior authorizations under the pharmacy and medical benefit. The program establishes copay penalties and incentives for members to participate in the InterveneRx specialty drug care management program following approval through the integrated prior authorization service, administered by InterveneRx.
Advertisement

"Our vision for managing costs and improving quality for our group clients and members has always been to pair risk management with advocacy services to help our members optimize their use of health care," stated Bill Ashley, CEO of Allied National. "With InterveneRx, we are able to successfully execute on this vision by changing our pharmacy and medical benefit designs to reward members for participation in an enhanced clinical prior authorization service that seamlessly integrates specialty drug care management. Allied can optimize improvements in safety, health outcomes, member engagement and cost savings for specialty drugs that our group clients want, and members need."

"We believe the InterveneRx platform as an integrated, clinically enhanced prior authorization system with specialty drug care management fills a significant gap in determining clinical value and efficacy of specialty drugs. We are pleased that such a forward thinking company as Allied National, Inc. will be implementing this platform to monitor and manage their specialty drug patients," said InterveneRx CEO Mark Steck, Pharm D, MBA.

Allied National, Inc. began implementing this program in January 2019 and expects to roll it out to all its clients nationwide by Q3 2019.

About InterveneRx InterveneRx is the leading digital health company focused on monitoring and improving complex care for patients utilizing specialty drugs. InterveneRx has developed the first ever automated specialty drug clinical pathways paired with a mobile App that is integrated with a clinically enhanced prior authorization service.    

About Allied Health, Inc. Allied National is one of the nation's oldest and most experienced third party administrators. They offer an array of services to agents, covered members and risk-bearing partners including: regulatory compliance; medical underwriting; agent appointment processing; policy issue; premium billing and collection; customer service; claim processing; health care management; and actuarial support.

 

SOURCE InterveneRx

Sponsored Post and Backlink Submission


Latest Press Release on Genetics & Stem Cells News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close